The Native Antigen Company

The Native Antigen Company, founded in 2010, is a biotechnology startup based in the United Kingdom that specializes in the development and manufacturing of critical reagents for human health. The company focuses on creating infectious disease antigens from bacteria and viruses, as well as producing recombinant forms of these antigens using their proprietary mammalian expression system.

Their antigens serve various purposes, including research and development, as well as bulk production for in-vitro diagnostic (IVD) manufacturers to incorporate into their immunoassays. With a particular expertise in flavivirus biology, the company has achieved several significant milestones. They were the first in the world to develop mammalian expressed Dengue virus NS1 antigens and subsequently achieved the same feat with Zika virus NS1 using the same platform. Additionally, the company has created a range of virus-like particles that are increasingly utilized as antigens for IVD applications.

Continuously innovating, The Native Antigen Company is leveraging their antigens to produce highly specific monoclonal antibodies and to develop immunoassays. Moreover, they offer these services on a contract basis to customers in need of a reliable source of high-quality recombinant or native protein.

As of now, the company's last investment and the associated investors are not publicly disclosed. However, with their pioneering work in the field of infectious disease antigens, the company presents an enticing opportunity for potential venture capital investment within the biotechnology sector.